Central Virology Laboratory, Public Health Services, Ministry of Health, Chaim Sheba Medical Center, Ramat Gan, Israel.
Infectious Diseases Unit, Chaim Sheba Medical Center, Ramat Gan, Israel.
Microbiol Spectr. 2023 Jun 15;11(3):e0022523. doi: 10.1128/spectrum.00225-23. Epub 2023 May 4.
In this report, we describe the first national scale multi-laboratory evaluation of monkeypox virus (MPXV) DNA commercial PCR kits. The objective of this study was to evaluate 2 kits by different diagnostic laboratories across Israel. Ten standardized samples were tested simultaneously using the Novaplex (15 laboratories) and Bio-Speedy (seven laboratories) kits. An in-house assay based on previously published reactions was used as reference. Comparison of the results showed high intra-assay agreement between laboratories, with small variations for most samples. The in-house assay had an analytical detection limit of less than 10 copies per reaction. While the 2 commercial kits were able to detect specimens with low viral loads similarly to the in-house assay, significant differences were observed, in the Cq values and relative fluorescence (RF), between the assays. The RF signal of the in-house and Bio-Speedy assays ranged between 5,000 and 10,000 RFU, while the signal in the Novaplex assay was less than 600 RFU. Due to the kit measurement protocol, the Cq values of the Bio-Speedy kit were 5 to 7.5 cycles lower than those of the in-house assay. On the contrary, the Cq values of the Novaplex kit were significantly higher than those of the in-house assay, with differences of 3 to 5 cycles per sample. Our results suggest that while all assays were similar in their overall sensitivity, direct comparison of Cq values between them may be misleading. To our knowledge, this is the first methodical evaluation of commercial MPX test kits. We therefore anticipate that this study would help diagnostic laboratories in choosing a specific MPX detection assay. To the best of our knowledge, this study is the first methodical evaluation of commercial kits designed for Monkeypox virus detection. This was done by performing the same tests using the same sample set in multiple laboratories, simultaneously, on a national scale. It therefore provides important and unique information on the performance of such kits and provides a guideline for choosing the assay of choice for monkeypox virus diagnosis in a standard diagnostic laboratory. It also demonstrates potential complications when trying to compare the results of different assays, even when testing exactly the same samples, under identical conditions.
在本报告中,我们描述了首次针对猴痘病毒 (MPXV) DNA 商业 PCR 试剂盒的全国范围内多实验室评估。本研究的目的是由以色列各地的不同诊断实验室评估 2 种试剂盒。使用 Novaplex(15 个实验室)和 Bio-Speedy(7 个实验室)试剂盒同时测试 10 个标准化样本。使用先前发表的反应的内部检测作为参考。比较结果表明,实验室之间的内部分配一致性很高,大多数样本的差异很小。内部检测的分析检测限小于每个反应 10 个拷贝。虽然 2 种商业试剂盒能够像内部检测一样检测到低病毒载量的标本,但在 Cq 值和相对荧光(RF)方面,各检测之间存在显著差异。内部和 Bio-Speedy 检测的 RF 信号在 5000 到 10000 RFU 之间,而 Novaplex 检测的信号小于 600 RFU。由于试剂盒测量协议,Bio-Speedy 试剂盒的 Cq 值比内部检测低 5 到 7.5 个循环。相反,Novaplex 试剂盒的 Cq 值明显高于内部检测,每个样本差异 3 到 5 个循环。我们的结果表明,虽然所有检测在总体灵敏度方面相似,但直接比较它们之间的 Cq 值可能会产生误导。据我们所知,这是首次对商业 MPX 检测试剂盒进行系统评估。因此,我们预计这项研究将有助于诊断实验室选择特定的 MPX 检测检测。据我们所知,这是首次对用于猴痘病毒检测的商业试剂盒进行系统评估。这是通过在全国范围内的多个实验室同时使用相同的试剂盒和相同的样本集进行相同的测试来完成的。因此,它提供了有关此类试剂盒性能的重要且独特的信息,并为在标准诊断实验室中选择用于猴痘病毒诊断的检测方法提供了指南。它还展示了当尝试比较不同检测的结果时,即使在相同条件下测试完全相同的样本,也会出现潜在的并发症。